pISSN: 1000-467X eISSN: 1944-446X CN: 44-1195/R |
New articles accepted recently Volume 35 Issue 8 From January 2002 |
祝贺Chinese Journal of Cancer (《癌症》) 影响因子再创新高
Chinese Journal of Cancer连续三年入选“中国最具国际影响力学术期刊”
The 4th Guangzhou International Symposium on Oncology Held
We are pleased to announce that the first Impact Factor of CJC is 2.155
U.S. Chinese Anti-Cancer Association-Asia Fund for Cancer Research 2015 Scholar Awards
巧用PowerPoint制作和修改医学论文图片——编辑部业务学习会整理
The New Horizons in Cancer Research Conference of AACR ended successfully in Shanghai
The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) Expanded
CJC wins the title of the 2012' Excellent International Impact Academic Journal of China
1 Altered expression of stromal interaction molecule (STIM)-calcium release-activated calcium channel protein (ORAI) and inositol 1,4,5-trisphosphate receptors (IP3Rs) in cancer: will they become a new battlefield for oncotherapy?
Jing Wen, Ying-Cheng Huang, Huan-Huan Xiu, Zhi-Ming Shan and Kang-Qing Xu
2 Cell-free circulating tumor DNA in cancer
Zhen Qin, Vladimir A. Ljubimov, Cuiqi Zhou, Yunguang Tong and Jimin Liang
3 Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma
Ying Guan, Shuai Liu, Han-Yu Wang, Ying Guo, Wei-Wei Xiao, Chun-Yan Chen, Chong Zhao, Tai-Xiang Lu and Fei Han
4 Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis
Ying Shi, Song-Ling Peng, Li-Fang Yang, Xue Chen, Yong-Guang Tao and Ya Cao
5 Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
Shan Wang, Yan Fu and Yongzhang Luo
6 Why some tumours trigger neovascularisation and others don’t: the story thus far
Omanma Adighibe, Russell D. Leek, Marta Fernandez-Mercado, Jiangting Hu, Cameron Snell, Kevin C. Gatter, Adrian L. Harris and Francesco Pezzella
7 Mechanisms of vascularization in murine models of primary and metastatic tumor growth
Edina Bugyik, Ferenc Renyi-Vamos, Vanessza Szabo, Katalin Dezso, Nora Ecker, Andras Rokusz, Peter Nagy, Balazs Dome and Sandor Paku
8 Future options of anti-angiogenic cancer therapy
Yihai Cao
9 Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation
Chao-Nan Qian, Min-Han Tan, Jun-Ping Yang and Yun Cao
1 Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs
Rishil J. Kathawala, Yi-Jun Wang, Charles R. Ashby Jr, Zhe-Sheng Chen
2 Small interfering RNA-based molecular therapy of cancers
Wei Guo, Wangbing Chen, Wendan Yu, Wenlin Huang, Wuguo Deng
3 The US Chinese Anti-Cancer Association and the National Foundation for Cancer Research recognize five young Chinese investigators with the 2014 USCACA-NFCR Scholar Awards
Wei Zhang, Lifang Hou, Li Yan, Wei Zhang, Michael Yi Wang, Shi-Yuan Cheng
4 Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
José Antonio López-Guerrero, Ignacio Romero, Andrés Poveda
5 Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment
Brittany C. Parker, Wei Zhang
Gastric cancer |
|
Edited by Yun Dai and Li Yan |
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tumor angiogenesis |
|
Edited by Francesco Pezzella
|
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Lung cancer |
|
 Edited by Lin Yan and Wei Zhang
|
Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.
|
CJC is now published by BioMed Central
© Chinese Journal of Cancer
ICP 备案序号:粤ICP备12079158号
Sun Yat-sen University Cancer Center
651 Dongfeng Road East,Guangzhou 510060, P.R.China
